vs
Avidbank Holdings, Inc.（AVBH）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
RECURSION PHARMACEUTICALS, INC.的季度营收约是Avidbank Holdings, Inc.的1.3倍（$35.5M vs $28.0M），Avidbank Holdings, Inc.净利率更高（32.3% vs -304.2%，领先336.5%）
Avidbank Holdings, Inc.是一家总部位于美国的金融控股公司，通过旗下子公司AvidBank运营，主要为加利福尼亚州的中小企业、企业主和高净值人群提供商业银行产品与服务，涵盖商业贷款、存款账户、现金管理及定制化融资方案，覆盖制造、科技、房地产等多个行业领域。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
AVBH vs RXRX — 直观对比
营收规模更大
RXRX
是对方的1.3倍
$28.0M
净利率更高
AVBH
高出336.5%
-304.2%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $28.0M | $35.5M |
| 净利润 | $9.0M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | — | -304.8% |
| 净利率 | 32.3% | -304.2% |
| 营收同比 | — | 681.7% |
| 净利润同比 | 65.9% | 39.6% |
| 每股收益（稀释后） | $0.84 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVBHRXRX
| Q1 26 | $28.0M | — | ||
| Q4 25 | $26.8M | $35.5M | ||
| Q3 25 | $48.0K | $5.2M | ||
| Q2 25 | $21.8M | $19.2M | ||
| Q1 25 | — | $14.7M | ||
| Q4 24 | — | $4.5M | ||
| Q3 24 | — | $26.1M | ||
| Q2 24 | — | $14.4M |
净利润AVBHRXRX
| Q1 26 | $9.0M | — | ||
| Q4 25 | $6.9M | $-108.1M | ||
| Q3 25 | $-37.7M | $-162.3M | ||
| Q2 25 | $5.8M | $-171.9M | ||
| Q1 25 | — | $-202.5M | ||
| Q4 24 | — | $-178.9M | ||
| Q3 24 | — | $-95.8M | ||
| Q2 24 | — | $-97.5M |
毛利率AVBHRXRX
| Q1 26 | — | — | ||
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% |
营业利润率AVBHRXRX
| Q1 26 | — | — | ||
| Q4 25 | — | -304.8% | ||
| Q3 25 | -110491.7% | -3327.6% | ||
| Q2 25 | 38.0% | -916.8% | ||
| Q1 25 | — | -1297.9% | ||
| Q4 24 | — | -4042.4% | ||
| Q3 24 | — | -377.1% | ||
| Q2 24 | — | -697.4% |
净利率AVBHRXRX
| Q1 26 | 32.3% | — | ||
| Q4 25 | 25.9% | -304.2% | ||
| Q3 25 | -78614.6% | -3135.3% | ||
| Q2 25 | 26.6% | -894.2% | ||
| Q1 25 | — | -1373.3% | ||
| Q4 24 | — | -3935.5% | ||
| Q3 24 | — | -367.5% | ||
| Q2 24 | — | -676.6% |
每股收益（稀释后）AVBHRXRX
| Q1 26 | $0.84 | — | ||
| Q4 25 | $0.65 | $-0.17 | ||
| Q3 25 | $-4.12 | $-0.36 | ||
| Q2 25 | $0.75 | $-0.41 | ||
| Q1 25 | — | $-0.50 | ||
| Q4 24 | — | $-0.56 | ||
| Q3 24 | — | $-0.34 | ||
| Q2 24 | — | $-0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $743.3M |
| 总债务越低越好 | $55.0M | $9.6M |
| 股东权益账面价值 | $287.2M | $1.1B |
| 总资产 | $2.5B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.19× | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资AVBHRXRX
| Q1 26 | — | — | ||
| Q4 25 | — | $743.3M | ||
| Q3 25 | — | $659.8M | ||
| Q2 25 | — | $525.1M | ||
| Q1 25 | — | $500.5M | ||
| Q4 24 | — | $594.4M | ||
| Q3 24 | — | $427.6M | ||
| Q2 24 | — | $474.3M |
总债务AVBHRXRX
| Q1 26 | $55.0M | — | ||
| Q4 25 | $60.0M | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M |
股东权益AVBHRXRX
| Q1 26 | $287.2M | — | ||
| Q4 25 | $278.4M | $1.1B | ||
| Q3 25 | $273.1M | $1.0B | ||
| Q2 25 | $204.4M | $919.1M | ||
| Q1 25 | — | $933.9M | ||
| Q4 24 | — | $1.0B | ||
| Q3 24 | — | $524.6M | ||
| Q2 24 | — | $584.4M |
总资产AVBHRXRX
| Q1 26 | $2.5B | — | ||
| Q4 25 | $2.5B | $1.5B | ||
| Q3 25 | $2.4B | $1.4B | ||
| Q2 25 | $2.4B | $1.3B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | — | $1.4B | ||
| Q3 24 | — | $726.5M | ||
| Q2 24 | — | $775.9M |
负债/权益比AVBHRXRX
| Q1 26 | 0.19× | — | ||
| Q4 25 | 0.22× | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | — | $-47.3M |
| 自由现金流率自由现金流/营收 | — | -133.1% |
| 资本支出强度资本支出/营收 | — | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-378.3M |
8季度趋势，按日历期对齐
经营现金流AVBHRXRX
| Q1 26 | — | — | ||
| Q4 25 | — | $-46.1M | ||
| Q3 25 | $12.4M | $-117.4M | ||
| Q2 25 | $10.7M | $-76.4M | ||
| Q1 25 | — | $-132.0M | ||
| Q4 24 | — | $-115.4M | ||
| Q3 24 | — | $-59.2M | ||
| Q2 24 | — | $-82.2M |
自由现金流AVBHRXRX
| Q1 26 | — | — | ||
| Q4 25 | — | $-47.3M | ||
| Q3 25 | $12.4M | $-117.6M | ||
| Q2 25 | $10.6M | $-79.6M | ||
| Q1 25 | — | $-133.8M | ||
| Q4 24 | — | $-116.7M | ||
| Q3 24 | — | $-63.8M | ||
| Q2 24 | — | $-83.4M |
自由现金流率AVBHRXRX
| Q1 26 | — | — | ||
| Q4 25 | — | -133.1% | ||
| Q3 25 | 25783.3% | -2272.5% | ||
| Q2 25 | 48.6% | -413.9% | ||
| Q1 25 | — | -907.4% | ||
| Q4 24 | — | -2567.7% | ||
| Q3 24 | — | -244.6% | ||
| Q2 24 | — | -578.5% |
资本支出强度AVBHRXRX
| Q1 26 | — | — | ||
| Q4 25 | — | 3.5% | ||
| Q3 25 | 72.9% | 4.7% | ||
| Q2 25 | 0.3% | 16.4% | ||
| Q1 25 | — | 12.4% | ||
| Q4 24 | — | 28.6% | ||
| Q3 24 | — | 17.5% | ||
| Q2 24 | — | 8.2% |
现金转化率AVBHRXRX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 1.84× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVBH
| Net Interest Income | $26.5M | 95% |
| Noninterest Income | $1.5M | 5% |
RXRX
暂无分部数据
